Clinical Trials Logo

Photodynamic Therapy clinical trials

View clinical trials related to Photodynamic Therapy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06468540 Not yet recruiting - Clinical trials for Central Serous Chorioretinopathy

Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Start date: June 15, 2024
Phase:
Study type: Observational

In this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. The visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. We will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.

NCT ID: NCT06437288 Not yet recruiting - Esophageal Cancer Clinical Trials

Hematoporphyrin Photodynamic Therapy for Esophageal Cancer

Start date: May 31, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness of photodynamic therapy using hematoporphyrin injection in treating recurrent or residual superficial esophageal cancer. The primary purpose is to assess the ability of this intervention to achieve complete response in these patients. The main question it aims to answer is: - What is the complete response rate at day 28 post-treatment with PDT using hematoporphyrin injection in patients with recurrent or residual superficial esophageal cancer? There is no comparison group in this single-arm study. Participants will: - Be adults aged 18-80 with recurrent or residual superficial esophageal cancer after prior treatment. - Receive an intravenous infusion of hematoporphyrin injection at a dose of 3mg/kg over 60 minutes. - Undergo 630nm laser irradiation 48-72 hours after the infusion. - Be assessed for complete response at day 28 post-treatment, as well as progression-free survival, overall survival, swallowing function, quality of life, and adverse events throughout the study.